Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas (ARVN) reported Q3 2024 financial results with revenue of $102.4 million, up from $34.6 million in Q3 2023. The company maintains $1.1 billion in cash and equivalents, expected to fund operations into 2027. Key developments include ongoing enrollment in multiple clinical studies for vepdegestrant in breast cancer, with topline data from VERITAC-2 Phase 3 trial expected in Q4 2024 or Q1 2025. Research and development expenses were $86.9 million, while general and administrative expenses increased to $75.8 million, including a $43.4 million lease termination loss.
Arvinas, a clinical-stage biotechnology company, held its third annual Arvinas Impact Day, a company-wide day of service. Employees from 16 states participated in various volunteer activities across the Greater New Haven area and beyond. The event aligns with Arvinas' core values and aims to make a positive impact in local communities.
Highlights from the day include:
- Save the Sound: Collected over 287 pounds of trash to protect local wildlife and environments
- Boys and Girls Club of Greater New Haven: Beautified indoor and outdoor spaces at two locations
- Friends of East Rock Park: Maintained walking paths by laying crushed stone and cutting back brush
- Employee-Selected Activities: Ranged from food bank support to animal shelters and neighborhood clean-ups
John Houston, Ph.D., Chairperson, CEO, and President at Arvinas, expressed pride in the employees' dedication and enthusiasm in supporting vital community organizations.
Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has announced its upcoming third quarter 2024 financial results and corporate update webcast. The event is scheduled for Wednesday, October 30, 2024, at 8:00 a.m. ET.
Investors and interested parties can access the live webcast through the 'Events and Presentations' section on the company's investor page. For those unable to attend the live event, a replay will be made available on the Arvinas website following the presentation.
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two upcoming investor conferences:
- The Wells Fargo Healthcare Conference on September 5, 2024, featuring a fireside chat with Ian Taylor, Ph.D., President of R&D, and Randy Teel, Ph.D., Chief Business Officer.
- The Cantor Global Healthcare Conference on September 19, 2024, with Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, participating in a fireside chat.
Both presentations will be available via live audio webcast on the company's website and through provided links. This engagement with investors highlights Arvinas' commitment to transparency and shareholder communication.
Arvinas (NASDAQ: ARVN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment in VERITAC-3 Phase 3 trial lead-in for vepdegestrant in first-line ER+/HER2- metastatic breast cancer
- VERITAC-2 Phase 3 trial enrollment completion expected in Q4 2024, with topline data in Q4 2024/Q1 2025
- Received $150 million from Novartis for ARV-766 license and AR-V7 program sale
- Q2 revenue: $76.5 million, up from $54.5 million in Q2 2023
- Cash position: $1.23 billion as of June 30, 2024
- Sufficient funding into 2027
The company continues to advance its PROTAC protein degradation platform across multiple indications.
Arvinas (NASDAQ: ARVN) appoints Andrew Saik as Chief Financial Officer and Treasurer, effective June 24, 2024. Saik, an experienced biopharma finance executive, previously served as CFO at Intercept Pharmaceuticals where he led significant financial restructuring efforts. At Arvinas, he will focus on building financial systems and infrastructure necessary for transitioning to a commercial-stage biotech and managing ongoing clinical-stage programs. In connection with his appointment, Saik received an inducement grant of options to purchase 94,418 shares and a restricted stock unit for 61,409 shares, under Nasdaq Listing Rule 5635(c)(4).
Arvinas announced new preclinical data presentations for its investigational PROTAC® programs targeting BCL6 and LRRK2. The data were unveiled at the European Hematology Association 2024 Annual Congress and the Biennial International LRRK2 Meeting. Key findings for ARV-393, targeting BCL6, showed promising anti-tumor activity in B-cell lymphoma models. ARV-393 demonstrated potent BCL6 protein degradation and tumor growth inhibition in various diffuse large B-cell lymphoma (DLBCL) subtypes. Additionally, the LRRK2 degrader program highlighted significant potential in treating neurodegenerative diseases, showing effective LRRK2 degradation with a favorable safety profile compared to experimental inhibitors. Both ARV-393 and the oral PROTAC LRRK2 degrader, ARV-102, are currently in phase 1 clinical trials.
Arvinas announced two key promotions: Ian Taylor, Ph.D., is now President of Research and Development, while Angela Cacace, Ph.D., becomes Chief Scientific Officer.
Dr. Taylor has been with Arvinas since 2016, having held important roles at Bayer and Pfizer, and will oversee strategic inputs across Arvinas' pipeline. Dr. Cacace, joining in 2018, has over two decades of experience in neuroscience and oncology, and was pivotal in advancing Arvinas' PROTAC® technology, including ARV-102.
Both will report to CEO John Houston and lead further innovation and development within Arvinas, focusing on pioneering treatments in oncology and neuroscience.
Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focusing on targeted protein degradation, announced participation in two prominent investor conferences. On June 6, 2024, John Houston, Ph.D., CEO and President, and Noah Berkowitz, M.D., Ph.D., CMO, will join a fireside chat at the Jefferies Global Healthcare Conference in NYC.
The team will also attend the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami, featuring another fireside chat. Both events will be webcast live, accessible through Arvinas' website's Events + Presentations section.
Arvinas announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Congress. The event will be held from May 31 to June 4, 2024, in Chicago. The first abstract features initial results from a Phase 1/2 study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer. It will be presented on June 3, 2024, from 1:15 p.m. to 2:45 p.m. CDT under the Genitourinary Cancer category.
The second abstract involves TACTIVE-K, a Phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor degrader, in combination with Pfizer's investigational CDK4 inhibitor, PF-07220060, in ER+/HER2- advanced breast cancer. This will be presented on June 2, 2024, from 9:00 a.m. to 12:00 p.m. CDT in the Breast Cancer—Metastatic category. Abstracts can be accessed on the official ASCO website.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
